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Abstract
 
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones
that play an important role in stimulating postprandial insulin release from pancreatic 
 
β
 
-cells. Agents that either mimic
GLP-1 or prevent its degradation are now available for the treatment of Type 2 diabetes, and strategies to enhance
endogenous GLP-1 release are under assessment. As intestinal peptides have a range of actions, including appetite
regulation and coordination of fat metabolism, harnessing the enteric endocrine system is a promising new field for drug
development.
Diabet. Med. 25, 889–894 (2008)
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Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-
otropic polypeptide (GIP), are intestinal hormones secreted in
response to food ingestion, which stimulate the release of
insulin from pancreatic 
 
β
 
-cells. Together they account for the
finding that oral glucose is a more potent stimulus for insulin
secretion than intravenous glucose—the so-called ‘incretin’
effect [1]. They are biologically and therapeutically interesting
peptides, not only because of their potential anti-hyperglycaemic
effects in Type 2 diabetes, but also because GLP-1 reduces
appetite and GIP modulates how the body handles dietary fats.
The original finding that GLP-1 infusion increased insulin
release and reduced fasting plasma glucose and glucagon in
Type 2 diabetic subjects [2] resulted in the development of
the first GLP-1 receptor agonists, and the recent licensing of
exenatide for the treatment of Type 2 diabetes. Interestingly,
longer-term studies have shown that chronic therapy with
GLP-1 mimetics is also associated with beneficial effects on
body weight [3]. As the active form of GLP-1 is normally
degraded rapidly in the circulation by the enzyme dipeptidyl
peptidase 4 (DPP-4), drug design in the field of GLP-1-based
therapies is predominantly based around producing GLP-1
mimetics that are DPP-4 resistant, or pharmacologically
inhibiting the enzymatic activity of DPP-4 (e.g. Sitagliptin,
Vildagliptin) [4].
Both approaches have their drawbacks. The GLP-1 mimetics
currently under development are peptide derivatives that are
not orally available, and although a small molecule agonist
of the GLP-1 receptor has been described [5], it is not clear
whether similar small molecules could be developed that
would be suitable for human therapeutics. The potential
disadvantage of inhibiting DPP-4, by contrast, is that the
enzyme is responsible for the cleavage of a wide range of
plasma peptides, as well as having a role in the immune system,
and the full biological consequences of its chronic inhibition
remain uncertain. A third therapeutic strategy, currently
under exploration, is to stimulate the endogenous release of
GLP-1 from the intestinal L-cells. As proof of principle, it has
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recently been reported that a small molecule (AR231453),
which targets GPR119 on L-cells, stimulates GLP-1 release
and improves glucose tolerance in rodents, both on its own
and additively with a DPP-4 inhibitor [6]. It has not, however,
yet been demonstrated definitively that enhancing GLP-1
secretion in a subject with Type 2 diabetes would provide
a sufficient stimulus to improve glycaemia.
 
GLP-1 effects on pancreatic islet hormones
 
The principal therapeutic action of GLP-1 arises from its
ability to stimulate insulin release in a glucose-dependent
manner. It also stimulates 
 
β
 
-cell proliferation and reduces
 
β
 
-cell apoptosis [7], although it remains to be established
whether these actions contribute to the effectiveness of
GLP-1 mimetics 
 
in vivo
 
. The glucose-dependence of GLP-1
can be understood by considering insulin secretagogues as
either initiators or amplifiers of secretion (Fig. 1). Whereas
initiators, such as glucose, trigger insulin release by depolariz-
ing the plasma membrane and enabling an influx of calcium
that signals to the secretory vesicles to release their contents,
amplifiers only enhance secretion after it has first been initiated.
In the cases of GLP-1 and GIP, this is through their binding to
specific G-protein-coupled receptors on the 
 
β
 
-cell membrane,
which activate adenylate cyclase and increase cytoplasmic
cyclic adenosine monophosphate (cAMP) levels. cAMP has a
range of actions in the 
 
β
 
-cell, but probably enhances insulin
release via pathways dependent on both protein kinase A and
Epac proteins [8]. The physiological interaction between
initiators and amplifiers of insulin release is important
therapeutically, because sulphonylureas are initiators of
insulin release, and their action can therefore be enhanced by
GLP-1. In patients taking sulphonylureas (or their equivalents)
the glucose dependence of GLP-1 is lost [9], and the combina-
tion therapy can result in hypoglycaemic side effects.
In addition to the stimulation of insulin release, GLP-1 also
inhibits glucagon release and stimulates somatostatin secretion
[10]. Indeed, the inhibition of glucagon release by GLP-1 is
believed to contribute to the clinical effectiveness of GLP-1
mimetics for the treatment of Type 2 diabetes, as the hyperglu-
cagonaemia commonly seen in diabetes is partially responsible
for the raised glucose levels. Exactly how GLP-1 inhibits
glucagon release is unclear. GLP-1 receptors have been
detected in at least a subset of pancreatic 
 
α
 
-cells, and it has
been confirmed that GLP-1 dose-dependently inhibits
glucagon secretion from perfused pancreas preparations [10].
Yet the GLP-1 receptor in 
 
α
 
-cells is believed to be identical to
that in 
 
β
 
-cells, and its activation should similarly increase
cAMP concentrations. As elevated cAMP levels in 
 
α
 
-cells, as in
 
β
 
-cells, are generally believed to increase, not decrease,
hormone release [11], the inhibitory nature of GLP-1 on glucagon
secretion currently remains a paradox.
Despite the demonstration that GLP-1 receptors are expressed
in pancreatic 
 
β
 
-cells and that GLP-1 stimulates insulin release
 
FIGURE 1 Glucose-dependent stimulation of 
insulin release by glucagon-like peptide-1 
(GLP-1). At low glucose concentrations (left), 
intracellular [Ca2+] is low, and although 
stimulation by GLP-1 causes an increase in 
cyclic adenosine monophosphate (cAMP), this 
causes only small increases in [Ca2+] and 
minimal enhancement of insulin release 
(dashed arrows). The amount of insulin released 
is not enough to induce hypoglycaemia. 
At high glucose concentrations or in the 
presence of sulphonylureas (right), [Ca2+] is 
elevated, and the elevation of cAMP by GLP-1 
can then potently enhance the rate of insulin 
release, as well as further increasing [Ca2+].
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from islets and insulinoma cell lines 
 
in vitro
 
, it is by no means
certain that the entire physiological effect of endogenously
secreted GLP-1 is mediated by direct interaction of the
hormone with the islet cells. GLP-1 has a circulating half-life
of 1–2 min and is rapidly inactivated by DPP-4 in the splanchnic
bed and liver. The levels of active GLP-1 that reach the pancreas
are therefore significantly lower than those in the portal circu-
lation. Furthermore, even after a meal, the circulating levels of
GLP-1 are at the low end of the range needed to stimulate
 
β
 
-cells, and supraphysiological concentrations of exogenously
infused GLP-1 are employed to stimulate insulin release in
Type 2 diabetic subjects. Nevertheless, the relatively modest
elevation of circulating active GLP-1 levels achieved by
inhibiting DPP-4 has been clearly demonstrated to be
therapeutically useful in diabetes. These findings raise the
possibility that locally released GLP-1 may be more effective
than peripherally administered GLP-1, and that the primary
target of GLP-1 from the entero-endocrine cells may reside
closer to the site of its secretion within the splanchnic circula-
tion. In support of this idea, GLP-1 receptors have been
detected immunohistologically in human portal vein sections,
with corresponding GLP-1 receptor mRNA expression in the
nodose ganglion (the inferior ganglion of the vagus nerve)
[12], suggesting that GLP-1 receptors are expressed in
afferent branches of the vagus, including those innervating
the portal vein. However, the functional role of GLP-1
receptors within the alimentary tract and portal vein, and
their relative contribution to the incretin effect compared
with those located on the pancreatic 
 
β
 
-cell itself, remain to be
established.
 
GLP-1 effects on appetite
 
Since the early trials of GLP-1 in human subjects, it has been
apparent that the hormone not only increases insulin release
but also reduces appetite. Although a portion of the effect was
initially attributed to nausea associated with reduced gastric
emptying, it is now apparent that GLP-1 also acts on central
appetite circuits. GLP-1 receptors have been identified in
regions of the hypothalamus such as the arcuate nucleus [13],
which are known to be involved in appetite regulation, and it
is possible that these may respond to changes in circulating
GLP-1 levels. GLP-1 is also produced by subgroups of brain
stem neurons that have been shown to be activated by gastric
distension, and that project, in part, to the hypothalamus [13,14].
The role of central GLP-1 and its importance for appetite
control and glucose homeostasis remain to be fully elucidated.
 
GLP-1 secretion
 
GLP-1 is one of a family of hormones released from specialized
entero-endocrine cells situated in the epithelial layer of the
gastrointestinal tract. GLP-1-producing L-cells have been
identified in the jejunum, ileum and colon, with the highest cell
densities reported in the ileum and colon. The cells have an
apical membrane surface facing into the gut lumen, which may
be involved in sampling the passing nutrients, and secretory
vesicles located towards the basolateral surface. Together in
the same cells, and even in the same vesicles, it has been shown
that GLP-1 may colocalize with Peptide YY in the colon, and
with GIP in upper regions of the small intestine. Whether this
is the only difference between the GLP-1-producing cells from
different gut regions remains to be established. In all cells
producing GLP-1, there is also concomitant production of
GLP-2 and oxyntomodulin, as all three molecules are formed
when the proglucagon precursor is cleaved by prohormone
convertase 1/3. In pancreatic 
 
α
 
-cells, by contrast, prohormone
convertase 2 cleaves the same proglucagon molecule to
produce glucagon and a major proglucagon fragment containing
the GLP-1 and GLP-2 sequences.
The principal stimulus for GLP-1 release is food ingestion.
Elevation of peripheral GLP-1 levels can be detected within
10–15  min of eating, and persists for up to several hours,
depending on the nutritional composition of the meal. The
time-dependence of GLP-1 secretion may reflect, at least in
part, the corresponding changes in nutrient levels at different
regions of the gut, as the food reaches, and stimulates, the
different populations of L-cells. However, several studies
have concluded that the early rise in GLP-1 following a meal
includes GLP-1 secreted from distal L-cells, which are stimulated
by neural or hormonal signals arising from proximally located
nutrient sensors.
In most studies on Type 2 diabetic subjects, GLP-1 levels are
reduced [15]. The commonest finding is that the later phase of
GLP-1 elevation is impaired in diabetes, but reduced fasting
levels have also been found in some studies. The mechanism
underlying impaired GLP-1 secretion has not been established,
but evidence suggests that it is a secondary consequence of the
diabetic state, as it was not, for example, found in first-degree
relatives of Type 2 diabetic subjects or in people with a previ-
ous history of gestational diabetes [16]. How diabetes affects
the L-cells, and whether the cells exhibit adaptive changes in
their density, distribution or function, will be interesting areas
for future research.
Like other intestinal epithelial cells, L-cells have a relatively
rapid turnover. They originate from pluripotent stem cells in
the crypts, differentiate as they migrate out of the crypts and
up the villi, and are shed from the villous tips after a lifetime of
5–7 days. This life cycle has interesting implications for
strategies aimed at targeting the cells as a therapy for Type 2
diabetes. It seems likely that even if the L-cells are damaged
acutely by the metabolic manifestations of diabetes, reversal
of the metabolic abnormalities would be accompanied by
restoration of normal GLP-1 secretion, as the previously
damaged L-cells would be replaced by a new L-cell population.
Unless the crypt stem cell population has been permanently
damaged or there is a primary defect in the L-cells, it would
seem likely that L-cells in metabolically controlled diabetes
would be as responsive to therapeutic stimulation as the
corresponding cells in healthy subjects.
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Mechanisms underlying GLP-1 secretion: 
 
in vivo
 
 and perfused gut studies
 
A number of studies addressing the pathways involved in GLP-
1 secretion have involved feeding humans or animals with a
range of nutrients, whilst measuring GLP-1 in the peripheral
circulation or portal vein. In other experiments, isolated
perfused segments of gut have been studied in anaesthetized
animals, and the GLP-1 concentrations measured in response
to nutrients instilled into the gut lumen, or to hormones and
neurotransmitters perfused through the mesenteric circulation.
Such studies have shown that GLP-1 secretion is triggered by
glucose, fats and proteins, and that the plasma levels reflect
both the calorific value and the nature of the ingested nutrients
[16]. Responses to monosaccharides have been shown to be
sodium-dependent, and not to require metabolism of the sugar
[17]; fats were found to be more effective when they contained
longer unsaturated acyl chains; and peptones as well as amino
acid mixtures replicated the secretory responses to proteins.
GLP-1 release was also triggered by hormones such as gastrin-
releasing peptide (the mammalian equivalent of bombesin)
and GIP (in mice, but not humans), as well as by acetylcholine
acting through muscarinic receptors.
 
Mechanisms underlying GLP-1 secretion: 
 
in 
vitro
 
 studies
 
GLP-1 secretion has been investigated 
 
in vitro
 
 using a variety
of cellular models, including fetal rat intestinal cell cultures,
canine intestinal cell cultures enriched for L-cells by elutria-
tion, and cell lines such as GLUTag, STC-1 and NCI-H716.
Unfortunately, it has been remarkably difficult to establish
reliable primary cultures of adult rodent intestinal cells
suitable for studies of enteroendocrine cell function. Of
the two murine cell lines, GLUTag and STC-1, the former is
perhaps the more reliable model of GLP-1 release, as it was
established from a colonic tumour from a transgenic
mouse expressing SV40 large T antigen driven by the pro-
glucagon promoter [18]. STC-1 cells were originally developed
as a model of secretin secretion and secrete a wide range of
enteric hormones in addition to GLP-1. NCI-H716 is notable
as the only human GLP-1-secreting cell line currently
available. Only a limited number of studies have been reported
using this cell type.
Studies on these L-cell models have yielded both consistent
and conflicting results. It is a uniform finding, for example,
that elevating cytoplasmic cAMP is a potent stimulus for GLP-1
release, whereas the effectiveness of changing the nutrient
concentrations is more variable. The robust responsiveness to
cAMP suggests that signals (hormonal, neural or nutritional)
coupled through G-protein-coupled receptors linked to
adenylate cyclase might similarly trigger GLP-1 release 
 
in vivo
 
.
Establishing whether L-cells also respond directly to nutrients
such as glucose is, however, critical to our understanding of
the overall behaviour of the entero-endocrine system.
GLUTag cells are electrically active, and fire action potentials
when stimulated with nutrients or raised cAMP concentra-
tions [19,20]. The coupling between nutrient changes and
hormone secretion is analogous to that found in other endocrine
cells, involving membrane depolarization, calcium entry and
calcium-dependent vesicle release (Fig. 2). As in pancreatic
 
β
 
-cells, agents that stimulate GLUTag cells can act as initiators
and/or amplifiers of GLP-1 release, raising the possibility that
L-cells 
 
in vivo
 
 may integrate signals from a variety of sources,
e.g. luminal, hormonal and neuronal. GLUTag cells are directly
glucose-sensitive in the sub-millimolar concentration range,
with half-maximum stimulation evident at ~0.2 m
 
M
 
 glucose
[21]. The detection mechanism involves both the closure of
adenosine triphosphate (ATP)-sensitive potassium channels and
the uptake of glucose by Na
 
+
 
-coupled glucose transporters.
However, as GLUTag cells are currently the only 
 
in vitro
 
L-cell model in which glucose dependence has been clearly
demonstrated, the importance of direct glucose sensing by
L-cells 
 
in vivo
 
, and the relative roles of K
 
ATP
 
 channels vs.
Na
 
+
 
-coupled glucose transporters or other glucose-sensing
mechanisms, remain to be established.
The currents generated by Na
 
+
 
-coupled glucose transporters
are particularly small relative to those that flow through ion
channels, because in a transporter the ionic movement is
directly coupled to the flux of substrate (e.g. two Na
 
+
 
 ions per
glucose molecule transported). Other related transporters
similarly couple the influx of a variety of nutrients, including
amino acids and di-/tri-peptides, to Na
 
+
 
 or proton gradients.
These uptake mechanisms play important roles in the absorptive
properties of the gut, because they enable nutrients to be
FIGURE 2 A working model of glucagon-like peptide-1 (GLP-1) release 
from the intestinal L-cell. Dietary nutrients stimulate GLP-1 release from 
intestinal L-cells, as a consequence of their Na+-coupled uptake and 
subsequent metabolism, which cause membrane depolarization (ΔΨ) and 
Ca2+ entry. Indirect signals from hormones and neurotransmitters can 
stimulate release by a variety of mechanisms, including elevation of cyclic 
adenosine monophosphate (cAMP) (which acts as both an initiator and 
an amplifier of GLP-1 release), and Ca2+ release from stores. GLP-1 
released at the basolateral membrane stimulates insulin release from 
pancreatic β-cells and reduces appetite.
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actively pumped out of the lumen against their concentration
gradients. The idea that they might also be involved in cell
signalling is more unusual. However, in GLUTag cells,
Na
 
+
 
-coupled glutamine and asparagine transport can also be
shown to trigger small depolarizing currents associated with
GLP-1 secretion [22], and the idea that Na
 
+
 
-dependent glucose
uptake can directly trigger GLP-1 release is supported by
previous observations that non-metabolizable substrates of
the intestinal glucose transporters trigger GLP-1 release from
perfused intestinal preparations. It is therefore possible that
L-cells 
 
in situ
 
 could sense luminal nutrients via the small
depolarizing currents generated by nutrient influx at their
apical membranes, generating electrical signals that could be
directly coupled to hormone release.
 
Physiological relevance
 
The incretin effect, which is responsible for up to 50% of the
normal release of insulin following oral glucose ingestion, is
significantly reduced in Type 2 diabetes [23], due both to the
diabetes itself and to concomitant obesity [24]. This is believed
to be a consequence of the impaired GLP-1 secretion described
above, combined with reduced responsiveness of the islets
to GIP. Interestingly, the insensitivity to GIP appears to be a con-
sequence of receptor down-regulation at the 
 
β
 
-cell plasma mem-
brane, and recent reports have suggested that it may be reversible
upon restoration of normoglycaemia [25]. Stimulating the release
of incretin hormones might therefore be a rational potential
therapeutic strategy in Type 2 diabetes, provided that the entero-
endocrine axis is not severely impaired by ongoing poor gly-
caemic control. Indeed, the success of certain forms of bariatric
surgery in lowering glucose levels in diabetic subjects, as well
as in reducing appetite more generally, is widely attributed to the
enhanced physiological release of entero-endocrine hormones
such as GLP-1 and PYY [26]. Taken together with the known
clinical effectiveness of GLP-1 mimetics and DPP-4 inhibitors in
Type 2 diabetes, the data suggest that exploring the opportunities
to stimulate the entero-endocrine axis 
 
in vivo
 
 might reveal
exciting new therapeutic possibilities. Identifying and targeting
G-protein-coupled receptors expressed specifically in the intest-
inal L-cells will be exciting areas for future drug development.
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